Human leukocyte antigen-G in ankylosing spondylitis and the response after tumour necrosis factor-α blocker therapy

Chun Hsiung Chen, Hsien Tzung Liao, Hung An Chen, Chin Hsiu Liu, Toong Hua Liang, Chin Tien Wang, Chang Youh Tsai, Chung Tei Chou

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objective. To investigate the role of HLA-G in AS. Methods. Serum levels of soluble HLA-G (sHLA-G) were measured in 80 AS patients and 30 healthy controls. The expression of HLA-G on the peripheral blood mononuclear cell (PBMC) surface was investigated in the same 80 AS patients and 40 healthy controls by flow cytometry. The response of HLA-G after 3 months of TNF-α blocker therapy (adalimumab) was evaluated in 14 AS patients. We evaluated Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Patient Global Score (BAS-G), physical mobility, ESR and CRP levels. Results. Serum levels of sHLA-G were significantly lower in 80 AS patients than 30 healthy controls [mean (S.D.) 22.47 (26.8) vs 34.78 (32.01) U/ml, P=0.028], and correlated significantly with modified Schober index (r=0.326; P=0.009), chest expansion (r=0.319; P=0.011), lateral lumbar flexion (r=0.377; P=0.002), cervical rotation (r=0.396; P=0.004), whereas inversely correlated with fingertip-to-floor distance (r=-0.282; P=0.026) and tragus-to-wall distance (r=-0.270; P=0.031). The expression of HLA-G on PBMCs was significantly higher in 80 AS patients than 40 healthy controls [mean (S.D.) 18.5 (6.10)% vs 15.41 (4.84)%; P=0.012], and correlated significantly with ESR (r=0.421; P <0.001) and CRP (r=0.419; P <0.001). The expression of HLA-G on PMBCs decreased significantly after 3 months of adalimumab therapy [third month vs baseline, 13.46 (5.38)% vs 19.87 (7.31)%; P=0.016]. Conclusions. Lower serum levels of sHLA-G contribute to susceptibility to AS, and predispose to poor spinal mobility. The expression of HLA-G on PMBCs is up-regulated in AS, correlates with acute phase reactants and decreases after TNF-α blocker therapy, suggesting an index of disease activity.

Original languageEnglish
Article numberkep360
Pages (from-to)264-270
Number of pages7
JournalRheumatology
Volume49
Issue number2
DOIs
Publication statusPublished - Feb 2010
Externally publishedYes

Fingerprint

HLA-G Antigens
Ankylosing Spondylitis
HLA Antigens
Tumor Necrosis Factor-alpha
Baths
Therapeutics
Serum
Acute-Phase Proteins
Blood Cells
Flow Cytometry
Thorax

Keywords

  • Ankylosing spondylitis
  • Disease activity
  • HLA-G
  • Mononuclear cells
  • Spinal mobility
  • TNF-α blocker

ASJC Scopus subject areas

  • Rheumatology
  • Pharmacology (medical)

Cite this

Chen, C. H., Liao, H. T., Chen, H. A., Liu, C. H., Liang, T. H., Wang, C. T., ... Chou, C. T. (2010). Human leukocyte antigen-G in ankylosing spondylitis and the response after tumour necrosis factor-α blocker therapy. Rheumatology, 49(2), 264-270. [kep360]. https://doi.org/10.1093/rheumatology/kep360

Human leukocyte antigen-G in ankylosing spondylitis and the response after tumour necrosis factor-α blocker therapy. / Chen, Chun Hsiung; Liao, Hsien Tzung; Chen, Hung An; Liu, Chin Hsiu; Liang, Toong Hua; Wang, Chin Tien; Tsai, Chang Youh; Chou, Chung Tei.

In: Rheumatology, Vol. 49, No. 2, kep360, 02.2010, p. 264-270.

Research output: Contribution to journalArticle

Chen, CH, Liao, HT, Chen, HA, Liu, CH, Liang, TH, Wang, CT, Tsai, CY & Chou, CT 2010, 'Human leukocyte antigen-G in ankylosing spondylitis and the response after tumour necrosis factor-α blocker therapy', Rheumatology, vol. 49, no. 2, kep360, pp. 264-270. https://doi.org/10.1093/rheumatology/kep360
Chen, Chun Hsiung ; Liao, Hsien Tzung ; Chen, Hung An ; Liu, Chin Hsiu ; Liang, Toong Hua ; Wang, Chin Tien ; Tsai, Chang Youh ; Chou, Chung Tei. / Human leukocyte antigen-G in ankylosing spondylitis and the response after tumour necrosis factor-α blocker therapy. In: Rheumatology. 2010 ; Vol. 49, No. 2. pp. 264-270.
@article{5a2f242557964989850a546784de6566,
title = "Human leukocyte antigen-G in ankylosing spondylitis and the response after tumour necrosis factor-α blocker therapy",
abstract = "Objective. To investigate the role of HLA-G in AS. Methods. Serum levels of soluble HLA-G (sHLA-G) were measured in 80 AS patients and 30 healthy controls. The expression of HLA-G on the peripheral blood mononuclear cell (PBMC) surface was investigated in the same 80 AS patients and 40 healthy controls by flow cytometry. The response of HLA-G after 3 months of TNF-α blocker therapy (adalimumab) was evaluated in 14 AS patients. We evaluated Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Patient Global Score (BAS-G), physical mobility, ESR and CRP levels. Results. Serum levels of sHLA-G were significantly lower in 80 AS patients than 30 healthy controls [mean (S.D.) 22.47 (26.8) vs 34.78 (32.01) U/ml, P=0.028], and correlated significantly with modified Schober index (r=0.326; P=0.009), chest expansion (r=0.319; P=0.011), lateral lumbar flexion (r=0.377; P=0.002), cervical rotation (r=0.396; P=0.004), whereas inversely correlated with fingertip-to-floor distance (r=-0.282; P=0.026) and tragus-to-wall distance (r=-0.270; P=0.031). The expression of HLA-G on PBMCs was significantly higher in 80 AS patients than 40 healthy controls [mean (S.D.) 18.5 (6.10){\%} vs 15.41 (4.84){\%}; P=0.012], and correlated significantly with ESR (r=0.421; P <0.001) and CRP (r=0.419; P <0.001). The expression of HLA-G on PMBCs decreased significantly after 3 months of adalimumab therapy [third month vs baseline, 13.46 (5.38){\%} vs 19.87 (7.31){\%}; P=0.016]. Conclusions. Lower serum levels of sHLA-G contribute to susceptibility to AS, and predispose to poor spinal mobility. The expression of HLA-G on PMBCs is up-regulated in AS, correlates with acute phase reactants and decreases after TNF-α blocker therapy, suggesting an index of disease activity.",
keywords = "Ankylosing spondylitis, Disease activity, HLA-G, Mononuclear cells, Spinal mobility, TNF-α blocker",
author = "Chen, {Chun Hsiung} and Liao, {Hsien Tzung} and Chen, {Hung An} and Liu, {Chin Hsiu} and Liang, {Toong Hua} and Wang, {Chin Tien} and Tsai, {Chang Youh} and Chou, {Chung Tei}",
year = "2010",
month = "2",
doi = "10.1093/rheumatology/kep360",
language = "English",
volume = "49",
pages = "264--270",
journal = "Rheumatology",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Human leukocyte antigen-G in ankylosing spondylitis and the response after tumour necrosis factor-α blocker therapy

AU - Chen, Chun Hsiung

AU - Liao, Hsien Tzung

AU - Chen, Hung An

AU - Liu, Chin Hsiu

AU - Liang, Toong Hua

AU - Wang, Chin Tien

AU - Tsai, Chang Youh

AU - Chou, Chung Tei

PY - 2010/2

Y1 - 2010/2

N2 - Objective. To investigate the role of HLA-G in AS. Methods. Serum levels of soluble HLA-G (sHLA-G) were measured in 80 AS patients and 30 healthy controls. The expression of HLA-G on the peripheral blood mononuclear cell (PBMC) surface was investigated in the same 80 AS patients and 40 healthy controls by flow cytometry. The response of HLA-G after 3 months of TNF-α blocker therapy (adalimumab) was evaluated in 14 AS patients. We evaluated Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Patient Global Score (BAS-G), physical mobility, ESR and CRP levels. Results. Serum levels of sHLA-G were significantly lower in 80 AS patients than 30 healthy controls [mean (S.D.) 22.47 (26.8) vs 34.78 (32.01) U/ml, P=0.028], and correlated significantly with modified Schober index (r=0.326; P=0.009), chest expansion (r=0.319; P=0.011), lateral lumbar flexion (r=0.377; P=0.002), cervical rotation (r=0.396; P=0.004), whereas inversely correlated with fingertip-to-floor distance (r=-0.282; P=0.026) and tragus-to-wall distance (r=-0.270; P=0.031). The expression of HLA-G on PBMCs was significantly higher in 80 AS patients than 40 healthy controls [mean (S.D.) 18.5 (6.10)% vs 15.41 (4.84)%; P=0.012], and correlated significantly with ESR (r=0.421; P <0.001) and CRP (r=0.419; P <0.001). The expression of HLA-G on PMBCs decreased significantly after 3 months of adalimumab therapy [third month vs baseline, 13.46 (5.38)% vs 19.87 (7.31)%; P=0.016]. Conclusions. Lower serum levels of sHLA-G contribute to susceptibility to AS, and predispose to poor spinal mobility. The expression of HLA-G on PMBCs is up-regulated in AS, correlates with acute phase reactants and decreases after TNF-α blocker therapy, suggesting an index of disease activity.

AB - Objective. To investigate the role of HLA-G in AS. Methods. Serum levels of soluble HLA-G (sHLA-G) were measured in 80 AS patients and 30 healthy controls. The expression of HLA-G on the peripheral blood mononuclear cell (PBMC) surface was investigated in the same 80 AS patients and 40 healthy controls by flow cytometry. The response of HLA-G after 3 months of TNF-α blocker therapy (adalimumab) was evaluated in 14 AS patients. We evaluated Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Patient Global Score (BAS-G), physical mobility, ESR and CRP levels. Results. Serum levels of sHLA-G were significantly lower in 80 AS patients than 30 healthy controls [mean (S.D.) 22.47 (26.8) vs 34.78 (32.01) U/ml, P=0.028], and correlated significantly with modified Schober index (r=0.326; P=0.009), chest expansion (r=0.319; P=0.011), lateral lumbar flexion (r=0.377; P=0.002), cervical rotation (r=0.396; P=0.004), whereas inversely correlated with fingertip-to-floor distance (r=-0.282; P=0.026) and tragus-to-wall distance (r=-0.270; P=0.031). The expression of HLA-G on PBMCs was significantly higher in 80 AS patients than 40 healthy controls [mean (S.D.) 18.5 (6.10)% vs 15.41 (4.84)%; P=0.012], and correlated significantly with ESR (r=0.421; P <0.001) and CRP (r=0.419; P <0.001). The expression of HLA-G on PMBCs decreased significantly after 3 months of adalimumab therapy [third month vs baseline, 13.46 (5.38)% vs 19.87 (7.31)%; P=0.016]. Conclusions. Lower serum levels of sHLA-G contribute to susceptibility to AS, and predispose to poor spinal mobility. The expression of HLA-G on PMBCs is up-regulated in AS, correlates with acute phase reactants and decreases after TNF-α blocker therapy, suggesting an index of disease activity.

KW - Ankylosing spondylitis

KW - Disease activity

KW - HLA-G

KW - Mononuclear cells

KW - Spinal mobility

KW - TNF-α blocker

UR - http://www.scopus.com/inward/record.url?scp=77950396801&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950396801&partnerID=8YFLogxK

U2 - 10.1093/rheumatology/kep360

DO - 10.1093/rheumatology/kep360

M3 - Article

C2 - 20008091

AN - SCOPUS:77950396801

VL - 49

SP - 264

EP - 270

JO - Rheumatology

JF - Rheumatology

SN - 1462-0324

IS - 2

M1 - kep360

ER -